For Students : Beyond Phage Therapy: Expanding the Role of Bacteriophages in Modern Medicine

-

Beyond Phage Therapy: Expanding the Role of Bacteriophages in Modern Medicine

Bacteriophages, or phages, are viruses that infect bacteria. While their therapeutic potential in combating antibiotic-resistant infections has drawn increasing attention, their utility in medicine extends well beyond clinical phage therapy. Today, phages and their components are being explored in diagnostics, biofilm disruption, antimicrobial enzyme development, vaccine production, and even cancer immunotherapy. These applications are reshaping the biomedical landscape by offering targeted, efficient, and often biocompatible solutions to long-standing medical challenges.

Bacteriophages in the Fight Against Biofilms

Biofilms represent one of the most formidable barriers to effective bacterial eradication in clinical settings. These dense bacterial communities adhere to surfaces such as catheters, prosthetic joints, heart valves, and lung tissues, encapsulated in a protective extracellular matrix that renders them up to 1,000 times more resistant to antibiotics compared to planktonic bacteria.

Several phages naturally produce enzymes, including polysaccharide depolymerases and endolysins, capable of degrading the biofilm matrix. In recent studies, phage cocktails have been shown to reduce Pseudomonas aeruginosa biofilm biomass by over 90% in vitro (Harper et al., 2021). Moreover, combination therapies involving phages and antibiotics exhibit synergistic effects. For example, in a murine wound model, treatment with a phage-antibiotic combination reduced bacterial load and enhanced wound healing compared to monotherapy (Waters et al., 2017).

This strategy is especially promising in the management of chronic infections associated with cystic fibrosis, diabetic foot ulcers, and infected implants. Efforts are also underway to coat medical devices with biofilm-disruptive phages to prevent colonization altogether.

Applications in Food Safety and Decontamination

The use of phages in food microbiology has advanced significantly in the past two decades. Pathogens such as Listeria monocytogenes, Salmonella enterica, and Escherichia coli O157:H7 are major public health concerns, often linked to foodborne outbreaks with significant morbidity and economic impact. In the United States alone, Listeria is responsible for approximately 1,600 illnesses and 260 deaths annually (CDC, 2023).

Phage-based products such as ListShield™ and PhageGuard are approved for use on ready-to-eat meats, dairy products, and produce to reduce bacterial contamination. Clinical trials and field data have shown that phage applications can reduce surface Listeria counts by 2–4 log units without affecting taste, texture, or nutritional content (Hagens & Loessner, 2014). This makes phage biocontrol a compelling alternative to chemical preservatives, especially amid growing demand for natural and organic food safety solutions.

Phages as Diagnostic Tools

Genetically engineered bacteriophages are being developed as precise, rapid diagnostic tools for bacterial infections. These systems leverage phage specificity for their bacterial hosts and incorporate reporter genes, such as luciferase or fluorescent proteins, that are activated upon infection. Once the engineered phage infects a target bacterium, it induces a detectable signal within minutes to hours.

One of the most successful applications of this approach is the use of luciferase-expressing mycobacteriophages to detect Mycobacterium tuberculosis in clinical samples. This method, known as phage amplification assay, has shown higher specificity and comparable sensitivity to traditional culture-based diagnostics, while significantly reducing turnaround time (Jacobs et al., 1993).

Recent innovations include multiplexed biosensors using CRISPR-Cas systems triggered by phage activity, enabling the detection of antimicrobial resistance genes in clinical isolates. These tools are especially valuable in resource-limited settings where rapid, point-of-care diagnostics are essential.

Development of Phage-Derived Enzymes as Therapeutics

Phage lytic enzymes, or endolysins, are peptidoglycan hydrolases that disrupt bacterial cell walls during the phage lytic cycle. These enzymes can be purified and administered independently of whole phages to exert bactericidal effects.

Endolysins have demonstrated remarkable efficacy against Gram-positive bacteria, which lack the protective outer membrane found in Gram-negative organisms. For instance, the endolysin PlyC has been shown to kill Streptococcus pyogenes within seconds in vitro and to protect mice from systemic infection (Fischetti, 2018). Other engineered lysins have been optimized to penetrate Gram-negative membranes and are currently in preclinical and early clinical trials.

What distinguishes lysins from traditional antibiotics is their specificity. A single lysin can target a particular bacterial species without affecting commensal flora, significantly reducing the risk of dysbiosis and secondary infections. Moreover, lysins are less prone to resistance development because they target essential and conserved bacterial structures.

Emerging Roles in Vaccine Technology and Cancer Therapy

An underexplored but rapidly growing area of research involves using phage particles as platforms for vaccine development and immunotherapy. Phage display technology enables the presentation of peptide antigens on the phage capsid, inducing robust immune responses. This method has been used to generate experimental vaccines against infectious agents such as HIV, influenza, and SARS-CoV-2, as well as for tumor-associated antigens in oncology.

Furthermore, temperate phages are being investigated for their potential to modulate the host immune system or serve as delivery vectors for CRISPR-Cas antimicrobials. In cancer therapy, phage particles have been used to deliver antigens or immune-stimulating molecules directly to tumors or antigen-presenting cells, offering a new avenue for personalized immunotherapy.

Reference :https://www.sciencedirect.com/science/article/pii/S0169409X1830317X

Conclusion

Bacteriophages are proving to be far more than just natural enemies of bacteria. Their unique biological features—host specificity, self-replication, enzymatic arsenal, and genetic manipulability—make them powerful tools across a broad spectrum of medical applications. From preventing hospital-acquired infections through biofilm disruption to improving food safety, accelerating diagnostics, and powering next-generation therapeutics, phages are rapidly becoming indispensable allies in the biomedical arsenal.

The continued development of phage technologies, bolstered by advances in synthetic biology, AI-guided protein engineering, and high-throughput screening, holds promise not only for treating infections but also for transforming diagnostics, immunotherapy, and global public health strategies.

References :

  • Harper, D. R., Parracho, H. M. R. T., Walker, J., Sharp, R., Hughes, G., Werthén, M., Lehman, S., & Morales, S. (2021). Bacteriophages and biofilms. Antibiotics, 10(4), 503. https://doi.org/10.3390/antibiotics10040503

  • Waters, E. M., Neill, D. R., Kaman, B., Sahota, J. S., Clokie, M. R. J., Winstanley, C., Kadioglu, A., & Hall, A. J. (2017). Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa. Thorax, 72(7), 666–667.

  • Centers for Disease Control and Prevention (CDC). (2023). Listeria (Listeriosis). https://www.cdc.gov/listeria

  • Hagens, S., & Loessner, M. J. (2014). Phages of Listeria offer novel tools for biocontrol of Listeria monocytogenes in food. Journal of Food Protection, 77(2), 273–281.

  • Jacobs, W. R., Barletta, R. G., Udani, R., Chan, J., Kalkut, G., Sosne, G., Kieser, T., Sarkis, G. J., Hatfull, G. F., & Bloom, B. R. (1993). Rapid assessment of drug susceptibilities of Mycobacterium tuberculosis by means of luciferase reporter phages. Science, 260(5109), 819–822.

  • Fischetti, V. A. (2018). Development of phage lysins as novel therapeutics: A historical perspective. Viruses, 10(6), 310. https://doi.org/10.3390/v10060310


Comments

Post a Comment

Popular posts from this blog

The Phage Therapy in the spotlight !

-
Image
Bacteriophages: Ancient Predators and the Next Frontier in Medicine In the animated documentary The Deadliest Being on Planet Earth , the Kurzgesagt team delves into the world of bacteriophages—viruses that prey exclusively on bacteria. With vibrant visuals and precise narration, the video introduces viewers to an invisible ecosystem where microscopic hunters orchestrate life-and-death dramas that shape the biosphere. These entities, though virtually unknown to the general public, may soon become central to the future of medicine. At the heart of the video lies a paradox: bacteriophages (or "phages") are among the most abundant biological entities on Earth—outnumbering all other organisms combined—yet their therapeutic potential has been largely sidelined in the antibiotic era. The video outlines the historical trajectory of phage research, spotlighting Félix d’Hérelle’s early 20th-century work and the rise of phage therapy, only to show how it was later eclipsed by the dis...
Read more

History Part 7 : The Rise of Penicillin and the Fall of Phages: A Forgotten Chapter in Medical History

-
Image
Penicillin and the Eclipse of Phage Therapy in Western Medicine (1928–1950) Abstract: The period between the late 1920s and the mid-20th century witnessed a fundamental transformation in antimicrobial therapeutics. Bacteriophage therapy, once a promising solution to bacterial infections, saw increasing use in European clinics during the interwar years. However, the discovery and mass production of penicillin during World War II radically shifted clinical priorities. This article examines the rise of penicillin and the scientific, clinical, and industrial dynamics that led to the displacement of phage therapy in Western medical practice by 1950. Introduction: A Divided Therapeutic Landscape In the interwar period, Western medicine faced a crisis of infectious disease without a universal remedy. While chemical antiseptics and arsenical compounds like Salvarsan were used for certain infections, many remained untreatable. Bacteriophage therapy emerged as a candidate solution, particula...
Read more

History Part 1 : Phage Therapy and its discovery by Felix d'Hérelle

-
Image
Félix d’Hérelle: The Forgotten Father of Phage Therapy Picture of Félix d'Hérelle (Pasteur Institute) A Visionary in the Shadows of History In the annals of microbiology, certain names are carved into stone — Pasteur, Koch, Fleming. But among them, one figure remains unjustly obscured: Félix d’Hérelle, a self-taught microbiologist who, in 1917, discovered the existence of bacteriophages — viruses that infect and destroy bacteria. Through meticulous experimentation and bold clinical application, d’Hérelle not only identified a new biological entity, but pioneered one of the most promising alternatives to antibiotics: phage therapy. A Self-Made Scientist Born in 1873 in Montreal, d’Hérelle had no formal degree in science. Instead, he was an intellectual adventurer — multilingual, well-read, and ferociously curious. After working in Guatemala and Mexico on fermentation and agricultural microbiology, he returned to France where he joined the Pasteur Institute in Paris as an unpaid ...
Read more